Supernus to present interim Phase IIa data for SPN-817 on May 23

SUPERNUS PHARMACEUTICALS, INC.

Interim data from open-label Phase IIa study of SPN-817 for treatment-resistant seizures to be reviewed at webcast on May 23, 2024.
Webcast at 4:30 p.m. ET; replay and slides available for 60 days via company website.
No actual clinical results disclosed in this filing; full data release scheduled for the event.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.